Ⅰ～ⅢA期完全切除术后的老年非小细胞肺癌的预后分析

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To identify prognostic factors associated with survival in elderly patients with non-small cell lung cancer (NSCLC) after radical resection. Methods From August 2003 to August 2011, in Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, the clinical data of 82 elderly patients (≥65 years old) with pathologic stage Ⅰ-ⅢA underwent radical resection were retrospective analyzed. And the correlation between clinical characteristics and prognostic factors was evaluated by Cox proportional hazards regression analysis. Results The median of DFS was 38.28 months (95% CI: 15.583-60.967 months). 1, 2, 5-year DFS rates were 73.2%,57.3% and 35.4%, respectively. Cox regression analysis showed: pathological type, lymph node involvement and ACT status were identified as the independent factors influenced the prognosis (P ＜ 0.05). Conclusion Pathological type, lymph node involvement and ACT status are identified as the independent factors influencing the prognosis of NSCLC elderly patients.

Key words： Elderly Non-small cell lung cancer Disease-free survival Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MI Yuling1 HU Xingsheng1 WANG Ziping2 ZHU Yixiang1

Cite this article:

MI Yuling1 HU Xingsheng1 WANG Ziping2 ZHU Yixiang1. Retrospective analysis of prognostic factors in elderly patients with stage Ⅰ-ⅢA non-small cell lungcancer after radical resection[J]. 中国医药导报, 2017, 14(17): 84-87.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I17/84

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2015 [J]. CA Cancer J Clin，2015，65（1）：5-29.
[2] Maione P，Rossi A，Sacco PC，et al. Treating advanced non-small cell lung cancer in the elderly [J]. Ther Adv Med Oncol，2010，2（4）：251-260.
[3] Wisnivesky JP，Smith CB，Packer S，et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages Ⅱ-ⅢA lung cancer： observational cohort study [J]. BMJ，2011，343：d4013.
[4] Ganti AK，Williams CD，Gajra A，et al. Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer [J]. Cancer，2015，121（15）：2578-2585.
[5] Zhai X，Yang L，Chen S，et al. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer [J]. Cancer Med，2016，5（9）：2286-2293.
[6] Detterbeck FC，Boffa DJ，Tanoue LT. The new lung cancer staging system [J]. Chest，2009，136（1）：260-271.
[7] Sundararajan V，Henderson T，Perry C，et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality [J]. J Clin Epidemiol，2004，57（12）：1288-1294.
[8] Weksler B，Nason KS，Shende M，et al. Surgical resection should be considered for stage Ⅰ and Ⅱ small cell carcinoma of the lung [J]. Ann Thorac Surg，2012，94（3）：889-893.
[9] Douillard JY，Rosell R，De Lena M，et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer （Adjuvant Navelbine International Trialist Association [ANITA]）：a randomised controlled trial [J]. Lancet Oncol，2006，7（9）：719-727.
[10] Strauss GM，Herndon JE，Maddaus MA，et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer：CALGB 9633 with the Cancer and Leukemia Group B，Radiation Therapy Oncology Group，and North Central Cancer Treatment Group Study Groups [J]. J Clin Oncol，2008，26（31）：5043-5051.
[11] Park SY，Lee JG，Kim J，et al. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer [J]. J Cardiothorac Surg，2013，8：151-159.
[12] Paul S，Lee PC，Mao J，et al. Long term survival with stereotactic ablative radiotherapy （SABR） versus thoracoscopic sublobar lung resection in elderly people： national population based study with propensity matched comparative analysis [J]. BMJ，2016，354：i3570.
[13] Ganti AK，DeShazo M，Weir AB，et al. Treatment of non-small cell lung cancer in the older patient [J]. J Natl Compr Canc Netw，2012，10（2）：230-239.
[14] Cuffe S，Booth CM，Peng Y，et al. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly： a population-based study in Ontario，Canada [J]. J Clin Oncol，2012，30（15）：1813-1821.
[15] 蒋峰，胡振东，冯冬杰，等.1560例非小细胞肺癌患者多因素预后分析[J].临床肿瘤学杂志，2009，14（10）：908-911.
[16] 黄诚，吴标，张晶，等.363例晚期老年非小细胞肺癌预后因素分析[J].中国肿瘤临床与康复，2012，19（1）：1-4.
[17] 张子瑾，程刚，孙建坤，等.70岁以上老年人非小细胞肺癌的生存研究[J].中国肺癌杂志，2008，11（2）：231-235.
[18] 刘涵，李峻岭.替吉奥单药三线或多线治疗老年晚期非小细胞肺癌的临床观察[J].癌症进展，2016，14（4）：346-349.
[19] PORT Meta-Analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer [J]. Cochrane Database Syst Rev，2003（1）：CD002142.
[20] Koulaxouzidis G，Toufektzian L，Ashrafian L，et al. Does the addition of postoperative radiotherapy to adjuvant chemotherapy offer any benefit in patients with non-small cell lung cancer and mediastinal lymphadenopathy?[J]. Interact CardioVasc Thorac Surg，2017： ivw380. doi：10.1093/icvts/ivw380.
[21] Kim BH，Kim HJ，Wu HG，et al. Role of postoperative radiotherapy after curative resection and adjuvant chemo-therapy for patients with pathological stage N2 non-small-cell lung cancer： a propensity score matching analysis [J]. Clin Lung Cancer，2014，15（5）：356-364.